Skip navigation
Skip navigation

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: A phase 2, randomised, double-blind, placebo-controlled trial

Kumar, Rajeev; Ames, D

Description

Background PBT2 is a metal protein-attenuating compound that might reduce metal-induced aggregation of mutant huntingtin and has prolonged survival in a mouse model of Huntington’s disease. We aimed to assess the safety, tolerability, and effi cacy of PBT2 in patients with Huntington’s disease. Methods In this 26-week, randomised, double-blind, placebo-controlled trial, adults (≥25 years old) with early-stage to mid-stage Huntington’s disease were randomly assigned (1:1:1) by a centralised...[Show more]

CollectionsANU Research Publications
Date published: 2015
Type: Journal article
URI: http://hdl.handle.net/1885/102793
Source: The Lancet Neurology
DOI: 10.1016/S1474-4422(14)70262-5

Download

File Description SizeFormat Image
01_Kumar_Safety%2C_tolerability%2C_and_2015.pdf174.67 kBAdobe PDF    Request a copy


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  17 November 2022/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator